GlassScriptPhysician profile
Lydia Rodriguez Ortiz
NPI 1225088388
$2,377.08
in general payments reported to CMS, 2019-2025
13 companies · $625 in 2025
The $625 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $194 · 2021: $120 · 2022: $441 · 2023: $485 · 2024: $345 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.16 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $560.35 | 2020-2025 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $273.82 | 2019-2025 | Eliquis |
| Novo Nordisk INC | $262.83 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.94 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $222.71 | 2020-2024 | Xarelto, Tecvayli |
| Abbott Laboratories | $222.58 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $207.95 | 2023 | Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $128.45 | 2020-2023 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $95.47 | 2024-2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $92.42 | 2021-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $24.63 | 2023 | Steglatro, Segluromet, Steglujan |
| Pbg Puerto Rico LLC | $22.37 | 2021 | |
| Abbvie INC. | $21.56 | 2023 | Synthroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Rodriguez Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.